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In patients controlled with SFC250 Diskus bd, this double-blind, randomised 6-month study
compared continuing SFC250 to stepping down to either SFC100 bd or FP250 bd. Six hundred
and three patients previously using 1000 mg BDP (or equivalent) daily þLABA and controlled ac-
cording to investigator’s judgement were recruited. Patients received SFC250 bd during an 8-
week open run-in period. Four hundred and seventy six patients (mean ageZ 43 years, mean
FEV1Z 2.9 1.0) who fulfilled the randomisation criterion (‘Well-controlled’ asthma accord-
ing to the GOAL weekly definition for the last 2 weeks of the run-in period) entered a 24-week
treatment period. The statistical hypothesis was based on a non-inferiority of SFC100 or FP250
compared to SFC250. The main criterion was the change from baseline in morning PEF over
weeks 1e12 in the per-protocol population. The non-inferiority limit was 15 L/min. At inclu-
sion, the three treatment groups were well balanced. Mean morning PEF was 476, 470 and
465 L/min in the SFC250, SFC100 and FP250 groups, respectively. The adjusted mean change
in morning PEF over weeks 1e12 was þ1.76 2.43 L/min for SFC250, 3.07 2.32 L/min for
SFC100 and 16.51  2.46 L/min for FP250. SFC100 was at least as effective as SFC25039 17 84 26.
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Therapeutic strategies to maintain asthma control 1125(treatment difference 4.83 [12.39; 2.72], pZ 0.151) whereas FP250 was not (treatment
difference 18.27 [26.05; 10.49], p< 0.001). Similar results were observed over weeks
13e24 in morning PEF (SFC100eSFC250Z4.54 3.84, pZ 0.238; FP250eSFC250Z
20.11 3.92, p< 0.0001). Secondary endpoints showed a similar pattern. Over weeks 1e
12, SFC250 was significantly more effective than FP250 on evening PEF, daily symptoms and
bronchodilator use. There was no difference between SFC100 and SFC250. The mean annual
rate of moderate exacerbations was 0.16 in both SFC 250 and SFC 100 groups, and 0.21 in
FP 250 group (ns, Poisson analysis). All treatments were well tolerated.
Conclusion: In patients achieving asthma control with SFC250, stepping treatment down with
SFC100 was at least as effective on lung function and symptoms as continuing SFC250, whereas
FP250 was not.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic inflammatory disorder of hyper-
responsive airways. Symptoms and airflow limitation can
occur when the airways are exposed to a variety of stimuli.1
Control of asthma, as outlined by asthma management
guidelines,2e4 is the goal of the treatment.1,2 The interna-
tional Global Initiative for Asthma (GINA) guidelines2 recom-
mend that the aims of asthma management are to achieve
and maintain control of symptoms, to maintain normal activ-
ity levels, to maintain pulmonary function as close to normal
as possible, to prevent asthma exacerbations, to avoid
adverse effects from asthma medications and to prevent
asthma mortality. GINA has defined three levels of asthma
control (controlled, partly controlled or uncontrolled). The
Gaining Asthma Control (GOAL) study4 has shown that control
can be achieved in a majority of patients.
Due to the underlying airway inflammation, inhaled
corticosteroids (ICS) remain the cornerstone of mainte-
nance treatment medication, but if asthma control is
inadequate, adding a long-acting b2-agonist (LABA) has
been shown to provide a better clinical benefit than
increasing the ICS dose.5,6 In the GOAL study4 salmeterol/
fluticasone propionate combination was significantly
superior to fluticasone propionate alone in achieving both
‘Well- and Totally controlled’ asthma. In addition, ICSs
and LABAs have been shown to have complementary effects
when administered together.7
Once asthma control has been achieved, ongoing mon-
itoring is essential in order to assess that control is
maintained for a prolonged period (at least 3 months)
before considering stepping down to establish the lowest
effective dose of treatment.2,3
Few studies were available on the step-down approach
at the time the study was initiated. Should the LABA be
stopped with the ICS dose maintained, or should the ICS
dose be reduced whilst maintaining the LABA? Several
studies have shown that salmeterol allows a greater re-
duction in the dose of ICS when stepping down compared to
ICS alone.8e10 A long-term study also demonstrated that
a low-dose of ICS (200 mg/day) administered for one year
with a LABA did not show any significant difference with
a higher dose of ICS alone (800 mg/day) on asthma control
and sputum markers of inflammation.11,12
The objective of this prospective double-blind rando-
mised 24-week study in asthmatics whose asthma was‘‘well-controlled’’ with an ICS/LABA combination, was to
compare two step-down strategies (to reduce ICS dosing or
to withdraw the LABA) to the ICS/LABA combination
strategy maintenance at the same dosing regimen. The
methodology was based on a non-inferiority sequential
hierachized design in order to answer the following two
questions: (a) is stepping down a viable option when control
is achieved and maintained for 3 months and (b) if so, which
option is superior: withdrawing the LABA or maintaining the
LABA and reducing the ICS dose?Methods
Study design
This was a prospective multicentre randomised, three-arm,
24-week study. Patients were enrolled into an 8-week run-
in period and received an open-label treatment of salme-
terol/fluticasone propionate combination (SFC) 50/250 mg
twice daily. All previous asthma medications were
discontinued at entry into the run-in period, except the
short-acting bronchodilators previously used by the
patient as rescue medication and antihistamines which
could be continued if they were previously used for at least
4 weeks.
Patients whose asthma was assessed as ‘‘Well-
controlled’’ over the last 2 weeks of the run-in period,
were eligible to enter the treatment period and were
randomised to receive twice daily either SFC 50/250 mg
(SFC 250), SFC 50/100 mg (SFC 100) or fluticasone propionate
250 mg (FP 250) for a period of 24 weeks. Every morning and
evening, patients were required to complete a diary card to
record their morning and evening peak expiratory flow (best
of three measurements), rescue use and occurrence of
symptoms.
The primary endpoint was mean morning peak expira-
tory flow (PEF) over the first 12 weeks of treatment.
Secondary endpoints were morning PEF over the last 12
weeks of the treatment period, evening PEF, daily symp-
toms, short-acting bronchodilator use as rescue medica-
tion, exacerbations, forced expiratory volume in 1 s (FEV1)
and asthma control using the GOAL definitions of total
and well-control.4 Exacerbations were defined as follows:
Moderate exacerbationZworsening of asthma leading
to a prescription for a short use of oral corticosteroids.
1126 P. Godard et al.Severe exacerbationZworsening of asthma leading to
hospitalisation.
Patients
The study was approved by the relevant local ethics
committee, and all patients gave written informed consent.
Male and female subjects, at least 18 years old, with
a documented history of asthma (for at least 6 months),
whose asthma was controlled with the current treatment
(inhaled corticosteroids at a dose of 1000 mg of CFC beclo-
methasone dipropionate or equivalent and a long-acting
b2-agonist at recommended dose) at a stable dose for at
least 4 weeks, were enrolled into the run-in period. Pa-
tients were excluded from entry into the run-in period if
they had a smoking history of 10 pack-years or more, a re-
spiratory tract infection during the last 4 weeks prior to the
initial clinic visit (V1), acute asthma exacerbation requiring
emergency room treatment or hospitalisation within 4
weeks prior to V1, and/or use of oral/parenteral corticoste-
roids during the last 4 weeks prior to V1 (12 weeks for depot
corticosteroids), or any change in their asthma mainte-
nance treatment in the previous 4 weeks.
At the end of the run-in period, asthma control was
assessed and subjects were randomised if they fulfilled the
weekly criteria for ‘Well-controlled’ asthma (as defined in
GOAL4) during the last 2 weeks of the run-in period.
Key exclusion criteria for entry into the treatment
period were changes in asthma medication (excluding study
rescue medication), use of oral/parenteral or depot corti-
costeroids, respiratory tract infection and/or insufficient
asthma control according to daily record card or Asthma
Control Questionnaire (ACQ) and/or investigator’s judge-
ment regarding the suitability of a reduction in mainte-
nance treatment.
Statistical methods
The methodology was based on a non-inferiority, sequential
hierarchized design.
The primary efficacy endpoint was the variation in mean
morning PEF over the first 12 weeks of the treatment period
compared to the last 2 weeks of the run-in period
(baseline). In order to demonstrate non-inferiority and to
minimise the type-1 error rate, hierarchized tests were
performed: first, each of the step-down strategies (SFC 100
or FP 250) were tested versus SFC 250, based on the two-
sided 97.5% confidence interval (97.5% CI), in order to show
that SFC 100 and FP 250 were at least as effective as SFC
250. Then a comparison of SFC 100 versus FP 250 was made,
based on the 95% CI, if the previous non-inferiorities were
established. The non-inferiority margin which was used to
compare the lower bound of CI was set to 15 L/min.
The method of Jones et al.13 was used to estimate the
sample size needed, based on the variation of morning PEF.
The standard deviation (SD) was estimated at 35 L/min in
controlled asthmatic adults. With a power of 90% and
a two-sided 97.5 %CI, a total of 408 randomised and evalu-
able subjects (136 per arm) were required.
The safety population consisted of all subjects who
had received at least one dose of study medication. TheFull Analysis Set (FAS) population consisted of all subjects
who had received at least one dose of study medication
and for whom the assessment data for at least one
assessment criterion was available whilst the Per-
Protocol population (PP) consisted of all subjects in the
FAS who did not have any major protocol deviations. In
addition, a subset of patients was defined within PP
population where the assessment of control at inclusion
was based only on the DRC only and not on the inves-
tigator’s assessment; this population was named PPDRC.
This population was defined to provide additional explor-
atory data on patients with asthma that was, at least,
‘Well-controlled’ at randomisation according to the DRC.
Baseline was defined as the last 2 weeks of the run-in
period. Change from baseline in mean morning PEF over
weeks 1e12 was analysed using an analysis of covariance
(ANCOVA) with treatment group as factor and age, sex and
baseline value as covariates.
Since the primary efficacy analysis was a non-inferiority
analysis, it was conducted on the PP population. Morning PEF
over weeks 13e24, evening PEF, percentages of symptom-
free days, percentages of days and nights with no use of
rescue bronchodilator and clinic visit FEV1 were to be ana-
lysed in the same way on the FAS if normality assumptions
were met, otherwise the Wilcoxon test on ranks was to be
used. The total number of exacerbations and the percentage
of subjects with at least one exacerbation were analysed us-
ing a generalised linear model, assuming a Poisson distribu-
tion, adjusted on the on-treatment duration (offset
variable) and with age and sex as covariates. Asthma control
was assessed for each week and also over the last 8 weeks of
each of the two 12-week treatment periods (i.e. weeks 5e12
and weeks 17e24).
Statistical analyses were performed by using SAS version
8.2 (SAS Institute Inc, Cary, NC, USA).
Results
Population
One hundred and twenty-four centres assessed a total of
603 patients for eligibility. At the end of the run-in period,
475 were randomised and included in the treatment phase
(Fig. 1). Demographic characteristics were comparable in
the three groups; however, in the SFC 250 group, there
were more smokers and ex-smokers. Baseline characteris-
tics were similar for all groups for PEF, symptoms and res-
cue use. Asthma was overall controlled as shown by the
high percentage of symptom-free days, nights without
awakenings and rescue-free days, however, in the SFC 250
group there was a higher percentage of non-controlled pa-
tients at baseline (35.1%) compared to the SFC 100 group
(24.4%) and FP 250 group (28.6%) (Table 1).
There was a higher proportion of withdrawals during the
treatment period in the FP 250 group (20.1%) than in either
the SFC 250 (11.3%) or SFC 100 treated group (9.5%). The
most frequent reason given for patients in the FP 250 group
discontinuing was ‘‘lack of efficacy’’ (33% of withdrawals
versus 25% and 11% in SFC 100 and SFC 250, respectively).
Withdrawals occurred mainly during the second 12-week
treatment period.
Completed study (n=142) 
Assessed for eligibility and entered run-in
(n=603)  
Lost to follow up (n=10) 
Discontinued treatment (n=118)* 
- Adverse event (n=13) 
- Consent withdrawn (n=21) 
- Did not fulfil entry criteria (n=65) 
- Lack of efficacy (n=16) 
- Other (n=3) 
take any study medication 
* includes 1 patient who was randomised but did not 
Randomised and included in ITT population 
(n=475)
Fluticasone propionate  
250 µg (FP 250) 
n=159
Fluticasone propionate / salmeterol 
100 / 50 µg (FSC 100/50) 
n=157
Fluticasone propionate / salmeterol 
250 / 50 µg (FSC 250/50) 
n=159 
Lost to follow up (n=2) 
Discontinued intervention (n=28) 
- Adverse event (n=6) 
- Consent withdrawn (n=3) 
- Lack of efficacy (n=10) 
- Did not fulfil entry criteria (n=1) 
- Other (n=8)
Lost to follow up (n=3) 
Discontinued intervention (n=12) 
- Adverse event (n=3) 
- Consent withdrawn (n=2) 
- Lack of efficacy (n=4) 
- Other (n=3)
Lost to follow up (n=4) 
Discontinued intervention (n=14) 
- Adverse event (n=3) 
- Consent withdrawn (n=4) 
- Lack of efficacy (n=2) 
- Other (n=5) 
Completed study (n=129) Completed study (n=141) 
Analysed (n=154)Analysed (n=156)Analysed (n=154)
Excluded from Per protocol population  
   - Non controlled asthma although 
 randomised (n=46) 
Excluded from Per protocol population 
   -  Non controlled asthma although  
 randomised (n=28) 
Excluded from Per protocol population 
   -  Non controlled asthma although 
randomised (n=42)
Per protocol population (n=117) Per protocol population (n=129) Per protocol population (n=113) 
PPDRC population (n=84) PPDRC population (n=88) PPDRC population (n=102) 
Figure 1 Flow of patients in study.
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Primary outcome: Morning PEF (PP population)
SFC 100 was at least as effective as SFC 250 in maintaining
morning PEF over 12 weeks, whereas FP 250 was not. Patientstreated with the reference treatment SFC 250 had an adjusted
mean change in morning PEF over 12 weeks of 1.76 2.43 L/
min. The adjusted mean change was 3.07
2.32 L/min in the SFC 100 group and 16.51 2.46 L/min in
the FP 250 group. Compared to SFC 250, patients treated
Table 1 Patient characteristics at baseline (FAS population)
FSC 250/50 (nZ 154) FSC 100/50 (nZ 156) FP 250 (nZ 154)
Median age, years (minemax) 46.5 (18.0e81.0) 43.0 (18.0e75.0) 42.0 (18.0e77.0)
% Females 48.1 46.2 51.3
Smokers or ex-smokers 24.7% 21.3% 16.2%
Pre-bronchodilator FEV1 L mean (SD) 2.8 (0.9) 3.0 (1.0) 2.9 (1.0)
Pre-bronchodilator FEV1 (% predicted), mean (SD) 87.8 (18.2) 91.2 (17.8) 90.8 (17.2)
Reversibility of FEV1 (%) 4.9 4.3 3.0
Morning PEF L/min mean (SD) 465.6 (113.2) 467.9 (111.2) 463.7 (105.1)
% Symptom-free days, mean (SD) 90.2 (22.1) 94.8 (14.1) 91.2 (21.7)
% Days without rescue use, mean (SD) 89.6 (25.1) 95.7 (13.2) 93.3 (19.1)
% Nights without awakening, mean (SD) 97.6 (9.6) 97.7 (8.0) 98.0 (9.5)
Total control, n (%) 49 (31.8%) 61 (39.1%) 91 (39.6%)
Well-control, n (%) 51 (33.1%) 57 (36.5%) 49 (31.8%)
Uncontrolled, n (%) 54 (35.1%) 38 (24.4%) 44 (28.6%)
1128 P. Godard et al.with SFC 100 and FP 250 had a mean difference of4.83 L/min
(97.5% CI [12.39; 2.72], pZ 0.151) and 18.27 (97.5% CI
[26.05;10.49], p< 0.0001), respectively (Fig. 2). This dem-
onstrated the non-inferiority of SFC 100 versus SFC 250 whilst,
FP 250 failed to demonstrate non-inferiority versus SFC 250.
Secondary outcomes (FAS population)
Others results on PEF
The mean morning PEF change from baseline over weeks
13e24 was 5.54 2.76 L/min in the SFC 250 group and
1 L/min 2.68 in the SFC 100 group (SFC 100eSFC
250Z4.54 L/min 3.84, pZ 0.238). Conversely in the FP
250 group, morning PEF decreased by 14.6 2.79 L/min
(FP250eSFC250Z20.11 L/min 3.92,p< 0.0001) (Fig. 3).
A similar pattern was observed on evening PEF over
weeks 1e12 and 13e24 with no significant difference
between SFC 100 and SFC 250 and a significant difference
between FP 250 and SFC 250 in favour of SFC 250 (SFC 100e
SFC 250Z5.31 L/min 3.42, pZ 0.121 over weeks 1e12
and 2.65 L/min 3.92, pZ 0.498 over weeks 13e24; FP
250eSFC 250Z17.43 L/min 3.43, p< 0.0001 over
weeks 1e12 and 18.71 L/min 3.43, p< 0.0001 over
weeks 13e24).
Symptoms and rescue medication use
Over the first 12 weeks of the treatment period, the mean
percentage of symptom-free days remained stable in both
SFC 250 (from 90.2% to 89.4%) and SFC 100 groups (from1.8
-3.1
-16.5
-15
-20
-10
-5
0
5
SFC 50/250 SFC 50/100 FP 250
L/
m
in -4.8(-12.4; +2.7) p=0.151  
-18.3 (-26.0; -10.5) p<0.0001 
Figure 2 Adjusted mean changes in morning PEF between
baseline and week 12.94.8% to 93.2%). In the FP 250 group, the percentage of
symptom-free days decreased slightly from 91.2% to 85.8%.
The difference between FP 250 and SFC 250 was
statistically significant (pZ 0.012) whereas there was no
difference between SFC groups. A similar pattern was ob-
served over weeks 5e12 for the percentage of rescue-free
days (SFC 250 from 89.6% to 89.0%, SFC50/100 from 95.7%
to 93.5% and FP 250 from 93.6% to 88.2%). The difference
between FP 250 and SFC 250 was significant (pZ 0.014).
There was no difference between SFC groups.
No difference was found between groups on daily
symptoms and rescue use over weeks 13e24. The percent-
age of nights without awakening remained stable in the
three groups with no differences observed over the whole
24-week treatment period.
Pre-bronchodilator FEV1 and reversibility
FEV1 remained stable in the SFC50/100 group (from 91.2%
predicted at baseline to 92.2% at week 24) and slightly in-
creased in the SFC 250 group (from 87.8% predicted at base-
line to 90.3%. The difference between the two SFC groups
was not significant. The FEV1 slightly decreased in the FP
250 group with a significant difference versus SFC 250 (FP
250-SFC 250Z3.72% expressed as percentage of pre-
dicted values pZ 0.002 at week 12 and 4.55%, p< 0.001
at week 24).
Reversibility in FEV1 from baseline decreased in both SFC
groups (from 4.9% to 2.8% and from 4.3% to 2.8 % for SFC250-14.6
1.0
5.5
-20
-15
-10
-5
0 SFC 50/250
5
SFC 50/100 FP 250
10
L/
m
in
-4.5(-13.2; +4.1) p=0.238  
-20.1(-28.9; -11.3) p<0.001  
Figure 3 Adjusted mean changes in morning PEF between
baseline and week 24.
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in the FP 250 group.
Exacerbations
No subjects experienced a severe exacerbation during the
study. The mean annual rate of moderate exacerbations
was 0.16 in both SFC 250 and SFC 100 groups, and 0.21 in FP
250 group. A total of 5.8% of the subjects in the SFC 250
group reported at least one moderate exacerbation over 6
months compared with 7.7% of the subjects in the SFC 100
group and 10.4% of the subjects in the FP 250 group.
Fewer exacerbations were reported in patients of both SFC
groups in the PPDRC population than in the same treatment
group in the FAS population, whereas the percentage was
similar for the FP 250 group in both the FAS and PPDRC
populations. The difference between groups was not statisti-
cally significantwith3.6%ofthesubjects reportingat leastone
exacerbation over 6 months in the SFC 250 group compared
with5.9%and9.1% for SFC100andFP250groups, respectively.
Asthma control
At baseline, the three arms were somewhat different with
respect to the percentage of controlled/non-controlled
patients. There were less controlled (‘Total and Well-
controlled’) patients in the SFC 250 group than in either
the SFC 100 and FP 250 groups (Table 1). The percentage of
‘Totally controlled’ patients increased from 31.8% to 39.6%
in the SFC 250 group whilst the percentage of well-con-
trolled patients remained stable.
Assessment of sustained asthma control using the last 8-
weeks’ data from the two periods of 12-week treatment
(i.e. weeks 5e12 and weeks 17e24), showed a higher
percentage of patients with asthma that was ‘Totally
controlled’ in both SFC groups than in the FP 250 group
(21.4%, 26.5% and 9.7% over weeks 5e12 and 24.7%, 27.6%
and 13% over weeks 17e24 for SFC 250, SFC 100 and FP 250,
respectively). Similar results were observed for ‘Well-
controlled’ asthma (45.4%, 58.3%, 37.6% over weeks 5e12
and 44.2%, 58.3%, 37.6% over weeks 17e24 for SFC 250, SFC
100 and FP 250, respectively).
Based on the PPDRC population (i.e. excluding patients
not ‘Well-controlled’ at baseline based on an analysis of the
diary card data alone) the % of patients whose asthma was
at least ‘Well-controlled’ at week 24 was 85%, 92% and 77%,
respectively, for SFC 250, SFC 100 and FP 250. For patients
who were ‘Totally controlled’ at randomisation, the per-
centage of patients who maintained ‘Total control’ at week
24 was 73.5% for the SFC 250 group 62.3% for the SFC 100
group and 47.5% for the FP 250 group.
In patients exhibiting a loss of asthma control at week
24, 91% had at least two criteria involved in the loss of
control as observed in the GOAL study.4 The median time to
the loss of control based on one criterion of asthma control
was 1 week for PEF, 1e2 weeks for rescue use, 2e4 weeks
for daytime symptoms and night-time awakenings and 3.5e
9 weeks for exacerbations.Adverse events
All treatments were well tolerated. Adverse events were
reported by 31% subjects in the SFC 250 group, 29% subjectsin the SFC 100 group and 27% subjects in the FP 250 group.
The most common adverse events among all patients were
bronchitis, rhinitis and sinusitis. Four serious adverse
events were reported by three subjects in the SFC 250
group (one loss of consciousness, one car crash, one breast
cancer, one chest pain), no subjects in the SFC 100 group
and one subject in the FP 250 group (pulmonary embolism).
None was drug-related. There was no fatal serious adverse
event.Discussion
This study was based on a sequential hierarchized design
investigating step-down therapy strategies compared to
maintaining the treatment in asthmatics previously con-
trolled with a combination therapy for at least 3 months.
The study demonstrated that the better option for reducing
treatment in controlled asthma patients on an ICS/LABA
combination was to reduce the ICS dose and to maintain the
LABA.
These findings are similar to those of a previously
published study14 which directly compared the same step-
down strategies given for 12 weeks in patients uncontrolled
at inclusion but who achieved asthma control with SFC 250
twice daily. This last study concluded that SFC 100 twice
daily regimen was more effective than switching to FP
250, i.e. to an inhaled corticosteroid alone. The study did
not define the optimal control level nor the time when
a dose reduction should be attempted once control is
achieved, however the study suggested that when stepping
down, control was better maintained in patients who had
been controlled for longer.
Both studies were designed and powered for non-
inferiority comparison. In the published step-down study,
the authors were able to demonstrate superiority of SFC
100 over FP 250. At the time our study was designed, the
results of the previous step-down study14 were not known
and could not be considered in the analysis plan of our
study. A non-inferiority trial was justified considering the
main objective was to compare two step-down strategies
to the maintenance of the previous treatment (SFC 250)
which allowed achieving asthma control, whereas in the
study by Bateman et al. the main objective was to compare
two step-down therapies. Moreover, another study con-
ducted in controlled patients on high dose ICS15 demon-
strated that, when adopting a step-down approach,
a reduction in the ICS dose could be achieved without com-
promising asthma control. Considering these results, we ex-
pected minimal changes at 12 weeks in the two step-down
arms, and we hypothesised that approximately the same
number of patients would have a deterioration of asthma,
regardless of the step-down strategy, as compared to the
reference treatment SFC 250.
Morning PEF was chosen as primary endpoint because it
is easily performed and is a well established outcome
measure for monitoring asthma.2 Asthma control may
have been a more suitable endpoint, but, at the time our
study was designed, the GOAL study investigating guideline
derived control definition was not yet published. Moreover,
PEF in this study appears to be a good predictor of loss of
asthma control as supported by the observation that 91%
1130 P. Godard et al.of patients who lost control of their asthma failed not only
on PEF but at least on two criteria. PEF was also the first
criterion to fail, followed by rescue use, daytime symp-
toms, night-time awakenings and exacerbations, and can
be considered as the most sensitive in this population of
moderate asthmatics.
The selected non-inferiority limit for morning PEF of
15 L/min has been used in previous studies,16,17 and is in
accordance with European Guidelines.18,19 Previous studies
also considered standard deviation of 35 L/min as a reason-
able estimate in controlled patients.
Our study showed that SFC 100 was at least as effective
as SFC 250 whereas FP 250 was not, based on mean
morning PEF over the first 12-week period. The mean
difference between FP 250 and SFC 250 in morning PEF was
below the non-inferiority limit of the confidence interval
allowing the conclusion to be made regarding the superi-
ority of SFC 250, in line with recent guidelines concerning
switching from non-inferiority to superiority.18 The mean
change from baseline over 12 weeks in both step-down
groups was similar to that observed in the earlier step-
down study.14 The mean morning PEF remained stable in
the SFC 100 group and decreased in the FP 250 over 12
weeks. However, the comparison between these two
groups was not performed as planned a priori as the non-
inferiority of the main comparison versus SFC 250 was
not achieved.
Results on symptoms and rescue use also favoured
the step-down strategy with SFC 100 during the first
12-week treatment period. Both the percentages of
symptom-free and rescue-free days remained stable in
both SFC groups, whereas they decreased with the ICS
alone. No difference was observed between both SFC
groups and SFC 250 was significantly superior to FP 250,
despite a higher proportion of non-controlled patients in
the SFC 250 group at baseline which could have minimized
the potential difference between groups over the 12-week
period. These results confirm those previously published
over 12 weeks.14
An area of strength of this study was to provide data over
24 weeks. In the Bateman study, the authors expressed
concern that slow but steady deterioration might occur
over a longer period of follow-up. That was not observed in
our study. Over weeks 17e24, similar results to those over
weeks 5e12 were observed on PEF: there was no difference
between SFC groups and SFC 250 was significantly superior
to FP 250. On symptoms and rescue use, no difference was
noticed between the three treatment groups. This was due
to an improvement in the FP 250 group and may be
explained by the differences at baseline between groups
(i.e. a higher number of controlled subjects in the FP 250
group) and the higher proportion of withdrawals for ‘lack of
efficacy’ during the second 12-week treatment period in
the FP 250 group than in the SFC groups. The observed
differences in efficacy between SFC groups and FP 250
could be an underestimation of the actual differences as
the FP 250 group had more symptomatic patients discon-
tinued from the study. Moreover, the higher percentage of
withdrawals due to ‘lack of efficacy’ in the FP 250 group
was observed despite a higher percentage of controlled
patients and a lower reversibility of FEV1 at baseline in this
group than in the others which may also have minimized thedifference between groups. A lower percentage of with-
drawals for ‘lack of efficacy’ was observed in the SFC 250
group indicating a better efficacy.
Due to the higher percentage of uncontrolled patients in
the SFC250 group at baseline in the FAS population, asthma
control was also analysed in the PPDRC population (exclud-
ing uncontrolled patients at baseline). In the FAS popula-
tion, asthma control evaluated each week, was superior in
the SFC 100 group than in the FP 250 group over 24 weeks.
The percentage of ‘Well and Totally controlled’ patients
evaluated over 8 weeks (weeks 5e12 and 17e24) was
superior in both SFC groups compared to the FP 250 group.
The percentage was slightly superior in the SFC 100 group
than in the SFC 250 group. This small difference may be
explained by the differences observed at baseline (i.e. the
higher percentage of uncontrolled patients and smokers in
the SFC 250 group). However, in patients ‘Totally con-
trolled’ at randomisation, SFC 250 allowed more patients to
maintain ‘Total control’ at week 24 than SFC 100 and FP
250. Even though the study was not powered to detect
a difference in asthma control, these results confirm that
when a step-down strategy is chosen, then, a lower
strength of combination therapy is a better option than
withdrawing the LABA to maintain control. However, it
seems that the maintenance of the initial level of treat-
ment with SFC 250 gives slightly better results on the
maintenance of ‘Total control’. This finding should be
confirmed.
The percentage of patients with at least one
exacerbation was numerically higher in the FP 250 group;
however, due to the low frequency of exacerbations
during the trial there were no statistically significant
differences between groups. In the PPDRC population,
the overall incidence was lower than in the FAS popula-
tion, but the relative decreases were less in the FP 250
group than in the SFC groups. This suggests that SFC may
be more effective than FP alone in the prevention of
exacerbations which was also demonstrated in the GOAL
study.4
In this moderate asthmatic population, the loss of
control in the FP arm confirms that two controllers in-
cluding a LABA were needed to maintain asthma control
and were a better option than a high dose of ICS. Similar
findings were shown in the study published by Papi even if
in a mild population.20Conclusion
This study showed that, in asthmatic patients whose
asthma is controlled with salmeterol/fluticasone propio-
nate 50/250, a step-down strategy with salmeterol/
fluticasone propionate 50/100 is at least as effective as
maintaining a constant dose. This was not shown with
fluticasone propionate 250 alone. Also, stepping down
should be considered in patients with a sufficient level
of control. The differences were maintained over 24
weeks and confirmed the previously published results
supporting a step-down strategy which reduces the ICS
dosage and maintains the long-acting b2 agonist in patients
who have achieved and maintained control for at least 3
months.
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